lilly retatrutide trial Breaking: New data just released. TRIUMPH-1 study results on the triple agonist. Eli Lilly's clinical trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg Who got Eli Lilly retatrutide;

Other Body Changes From Ozempic: Ozempic Butt Like the face, other areas of the body with fat reserves may lose volume rapidly: Buttocks Arms Thighs Abdomen "Ozempic butt" is another trending concern, especially in patients who have experienced significant fat loss in the lower body, often leading to sagging skin which can be fixed with skin thightening treatments

The common ones include nausea, reduced appetite, stomach discomfort, and constipation or diarrhoea

You just need to find the path that works for you

Hair loss has been reported by some patients taking GLP-1 medications, but it is not considered a common side effect

Peptides 2018;100:4853.ArticlePubMed 108